Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Bombardier Proudly Shares the 30th Anniversary of Safety Standdown with an Industry-Wide Gathering in Wichita, Kansas

September 21, 2026

Get a closer look at the iPhone 18 Pro’s mechanical camera

September 21, 2026

HyOrc Completes Off-Site Modular Build of First Commercial Waste-to-Methanol Plant Bound for Porto

September 21, 2026

EnBW Deploys XCharge C7 480 kW Fast Chargers Across Its Nationwide Charging Network in Germany

September 21, 2026

Coinstore to List JMDT, Expanding Access to Privacy-Preserving Blockchain Infrastructure

September 21, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Fondaparinux Market Opportunity and Forecast Report 2025-2034: Orthopedic Surgeries and Demand for Anticoagulant Treatments Solidifying Future Growth Potential
Press Release

Fondaparinux Market Opportunity and Forecast Report 2025-2034: Orthopedic Surgeries and Demand for Anticoagulant Treatments Solidifying Future Growth Potential

By News RoomApril 10, 20254 Mins Read
Fondaparinux Market Opportunity and Forecast Report 2025-2034: Orthopedic Surgeries and Demand for Anticoagulant Treatments Solidifying Future Growth Potential
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, April 10, 2025 (GLOBE NEWSWIRE) — The “Fondaparinux Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034” report has been added to ResearchAndMarkets.com’s offering.

The Fondaparinux Market was valued at USD 691.9 million in 2024, and is projected to reach USD 1.32 billion by 2034, rising at a CAGR of 6.8%

The market expansion is fueled by the increasing incidence of thromboembolic disorders such as deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as the growing preference for effective anticoagulation therapies. Fondaparinux, a synthetic anticoagulant, plays a vital role in preventing and treating blood clots, offering a targeted mechanism of action with a lower risk of heparin-induced complications.

The rising number of surgical procedures, including orthopedic surgeries, further propels the demand for anticoagulant treatments, solidifying fondaparinux’s position as a key player in this segment. The expansion of healthcare infrastructure and the increased availability of cost-effective treatment options continue to support market growth. Additionally, favorable regulatory policies and the push for advanced anticoagulant therapies reinforce fondaparinux’s adoption across inpatient and outpatient settings.

The fondaparinux market is divided into branded and generic versions, with the generic segment maintaining a dominant position due to its affordability and widespread use. In 2024, the generic segment generated USD 439.3 million in revenue, highlighting its strong market presence. The demand for generic fondaparinux continues to rise as healthcare providers and patients seek cost-effective alternatives to branded drugs, particularly in cases requiring long-term anticoagulation therapy. With an increasing number of patients requiring continued blood clot prevention, generic formulations provide an accessible and budget-friendly solution, driving adoption across hospitals, clinics, and home care settings.

Segmentation by application reveals that fondaparinux is widely used for treating deep vein thrombosis (DVT), pulmonary embolism (PE), and acute coronary syndrome (ACS). In 2024, the DVT segment accounted for 47.8% of the market, reflecting the growing prevalence of DVT cases worldwide. Older adults and individuals with chronic health conditions face higher risks of clot formation, making effective anticoagulation therapy essential. Fondaparinux remains a preferred treatment due to its reliable efficacy, predictable pharmacokinetics, and the advantage of not requiring routine blood monitoring, unlike certain traditional anticoagulants.

The U.S. fondaparinux market generated USD 244.3 million in 2024 and is projected to reach USD 433.9 million by 2034. Several factors contribute to this expansion, including a high volume of orthopedic procedures, an aging population, and a rising prevalence of critical illnesses that necessitate anticoagulation therapy. The increasing adoption of advanced treatment protocols and the demand for safer, more efficient anticoagulants continue to drive fondaparinux’s market presence in the U.S., reinforcing its role in modern healthcare.

Comprehensive Market Analysis and Forecast

  • Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
  • Competitive landscape with Porter’s Five Forces and PESTEL analysis
  • Market size, segmentation, and regional forecasts
  • In-depth company profiles, business strategies, financial insights, and SWOT analysis

Companies Featured

  • Abbott Laboratories
  • Alchemia
  • Apotex
  • Aurobindo
  • Dr. Reddy’s Laboratories
  • Jiangsu Hengrui Medicine
  • Lupin Pharmaceuticals
  • Sandoz
  • ScinoPharm Taiwan
  • Viatris

Key Attributes:

Report Attribute Details
No. of Pages 132
Forecast Period 2024 – 2034
Estimated Market Value (USD) in 2024 $691.9 Million
Forecasted Market Value (USD) by 2034 $1320 Million
Compound Annual Growth Rate 6.8%
Regions Covered Global

Key Topics Covered:

Chapter 1 Methodology and Scope
1.1 Market scope and definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates and calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources

Chapter 2 Executive Summary
2.1 Industry 360 synopsis

Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising incidence of thromboembolic diseases
3.2.1.2 Increase in hip and knee transplant surgeries
3.2.1.3 Surge in aging population worldwide
3.2.2 Industry pitfalls and challenges
3.2.2.1 Side effects associated with fondaparinux
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Future market trends
3.7 Gap analysis
3.8 Porter’s analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, by Product Type, 2021-2034 ($ Mn)
5.1 Key trends
5.2 Branded
5.3 Generic

Chapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)
6.1 Key trends
6.2 Deep vein thrombosis
6.3 Pulmonary embolism
6.4 Acute coronary syndrome
6.5 Other applications

Chapter 7 Market Estimates and Forecast, by Distribution Channel, 2021-2034 ($ Mn)
7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.4 Asia-Pacific
8.4.1 China
8.4.2 India
8.4.3 Japan
8.4.4 Australia
8.4.5 South Korea
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.6 Middle East and Africa
8.6.1 Saudi Arabia
8.6.2 South Africa
8.6.3 UAE

For more information about this report visit https://www.researchandmarkets.com/r/j6fjnd

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Bombardier Proudly Shares the 30th Anniversary of Safety Standdown with an Industry-Wide Gathering in Wichita, Kansas

HyOrc Completes Off-Site Modular Build of First Commercial Waste-to-Methanol Plant Bound for Porto

EnBW Deploys XCharge C7 480 kW Fast Chargers Across Its Nationwide Charging Network in Germany

Coinstore to List JMDT, Expanding Access to Privacy-Preserving Blockchain Infrastructure

Winfield LLC Announces Launch of SweepBurger.com, a Free-to-Play Sweepstakes Casino With Notifications for New Sweepstakes

Canadian Designers Unite in Harmony as Cashmere Collection Announces its 2026 Roster

Zoomex to Host Traders After Party During TOKEN2049 Singapore, Connecting Traders and the Web3 Community

Einride Enters Strategic Collaboration with NVIDIA to Advance its Autonomous Trucking on NVIDIA Hyperion

Brown & Brown names Erik Templin to lead employee benefits across North America

Editors Picks

Get a closer look at the iPhone 18 Pro’s mechanical camera

September 21, 2026

HyOrc Completes Off-Site Modular Build of First Commercial Waste-to-Methanol Plant Bound for Porto

September 21, 2026

EnBW Deploys XCharge C7 480 kW Fast Chargers Across Its Nationwide Charging Network in Germany

September 21, 2026

Coinstore to List JMDT, Expanding Access to Privacy-Preserving Blockchain Infrastructure

September 21, 2026

Latest News

Winfield LLC Announces Launch of SweepBurger.com, a Free-to-Play Sweepstakes Casino With Notifications for New Sweepstakes

September 21, 2026

Canadian Designers Unite in Harmony as Cashmere Collection Announces its 2026 Roster

September 21, 2026

Zoomex to Host Traders After Party During TOKEN2049 Singapore, Connecting Traders and the Web3 Community

September 21, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version